APA (7th ed.) Citation

Guigay, J., Keilholz, U., Mesia, R., Vintonenko, N., Bourhis, J., & Auperin, A. (2015). PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC. Radiotherapy & Oncology, 114, 46. https://doi.org/10.1016/S0167-8140(15)34851-9

Chicago Style (17th ed.) Citation

Guigay, J., U. Keilholz, R. Mesia, N. Vintonenko, J. Bourhis, and A. Auperin. "PO-091: TPExtreme Randomized Trial: Docetaxel-Platinum(P)-Cetuximab(C) Versus 5FU-P-C in Recurrent/metastatic HNSCC." Radiotherapy & Oncology 114 (2015): 46. https://doi.org/10.1016/S0167-8140(15)34851-9.

MLA (9th ed.) Citation

Guigay, J., et al. "PO-091: TPExtreme Randomized Trial: Docetaxel-Platinum(P)-Cetuximab(C) Versus 5FU-P-C in Recurrent/metastatic HNSCC." Radiotherapy & Oncology, vol. 114, 2015, p. 46, https://doi.org/10.1016/S0167-8140(15)34851-9.